Home » Stocks » Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. (CRVS)

Stock Price: $4.20 USD -0.03 (-0.71%)
Updated Aug 4, 2020 8:00 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 117.40M
Revenue (ttm) n/a
Net Income (ttm) -45.60M
Shares Out 28.04M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $4.20
Previous Close $4.23
Change ($) -0.03
Change (%) -0.71%
Day's Open 4.16
Day's Range 4.00 - 4.40
Day's Volume 15,984
52-Week Range 1.01 - 6.88

More Stats

Market Cap 117.40M
Enterprise Value 60.90M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.04M
Float 13.89M
EPS (basic) -1.55
EPS (diluted) -1.55
FCF / Share -1.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 424,168
Short Ratio 0.24
Short % of Float 9.63%
Beta 2.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.99
Revenue n/a
Operating Income -46.99M
Net Income -45.60M
Free Cash Flow -37.97M
Net Cash 56.50M
Net Cash / Share 2.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -35.11%
ROE -64.91%
ROIC -81.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.20*
(119.05% upside)
Low
6.00
Current: $4.20
High
15.00
Target: 9.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-48.85-49.22-56.52-36.98-13.77-0.16
Net Income-46.67-46.94-55.66-36.38-31.34-0.16
Shares Outstanding29.3527.5120.4915.420.370.17
Earnings Per Share-1.59-1.71-2.72-2.36-83.86-0.95
Operating Cash Flow-37.32-40.99-46.21-27.86-11.33-0.10
Capital Expenditures-0.03-0.36-0.27-2.20-1.75-
Free Cash Flow-37.35-41.34-46.48-30.06-13.08-0.10
Cash & Equivalents77.9811590.0613594.3912.52
Total Debt3.19-----
Net Cash / Debt74.7911590.0613594.3912.52
Assets83.6511894.7814098.4612.53
Liabilities12.547.909.947.353.782.68
Book Value71.1111084.84133-31.10-0.16
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Corvus Pharmaceuticals, Inc.
Country United States
Employees 52
CEO Richard A. Miller

Stock Information

Ticker Symbol CRVS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRVS
IPO Date March 23, 2016

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.